what kind of sparks will there be when the government industry guidance fund encounters high-tech biomedical projects?
recently, the industrial guiding fund of the tonglu county government approved the investment project of the beijing sanyoulihe biological technology co., ltd.(北京三有利和泽生物科技有限公司), led by wu zuze, the academician of the chinese academy of sciences, on artificially reconstructing new hirudin and human odontogenic mesenchymal stem cells, and agreed to contribute 210.02 million yuan by stock equity and concessionary investment. wu zuze is a pioneer in experimental hematology research in china, who is the first one that obtained the growth factor of human stem cell and is known as the "father of chinese hematopoietic stem cells."
in the next five years, the company is expected to achieve 3-5 innovative medicines based on regenerative medicine in the clinical trial stage or approved for marketing. it will become a leading company in the stem cell regenerative medicine industry in china and boost the development of the life and health industry in tonglu county where the first stem cell new drug industrialization project base is planned to settle.